Stay Tuned!

Subscribe to our newsletter to get our newest articles instantly!

Tech News

Circle Pharma Achieves Major Milestone with the Selection of a Clinical Development Candidate Directly Inhibiting Cyclins A and B

  • CID-078 is a first-in-class oral macrocycle that drives synthetic lethality in a wide range of cancers
  • Circle expects to initiate clinical studies in 2024


Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the selection of CID-078 for its first clinical development program. CID-078 is the first-and-only-in-class dual inhibitor of Cyclins A and B,…

Source link


Techy Nerd

About Author

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Tech News

3 ways businesses can strike the ideal marketing and IT balance

We’re seeing two schools of thought emerge on how best to leverage data in the digital media landscape. The first
Software Tech News

Build Smart Biolinks with AI: Introducing the AI Biolink Creator

AI powered content for Bio Links and Marketing.